留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

前列腺癌尿液肿瘤标志物的研究进展

王诗钧 李英杰 文进

王诗钧, 李英杰, 文进. 前列腺癌尿液肿瘤标志物的研究进展[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2021-0774
引用本文: 王诗钧, 李英杰, 文进. 前列腺癌尿液肿瘤标志物的研究进展[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2021-0774
WANG Shijun, LI Yingjie, WEN Jin. Advances in Urinary Tumor Markers of Prostate Cancer[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2021-0774
Citation: WANG Shijun, LI Yingjie, WEN Jin. Advances in Urinary Tumor Markers of Prostate Cancer[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2021-0774

前列腺癌尿液肿瘤标志物的研究进展

doi: 10.12290/xhyxzz.2021-0774
基金项目: 

中国医学科学院中央级公益性科研院所基本科研业务费专项资金(2019XK320027);外国文教专家项目管理基金(G20190001645)

详细信息
    通讯作者:

    文进,E-mail:wjpumch@163.com

  • 中图分类号: R737.25;R730.4

Advances in Urinary Tumor Markers of Prostate Cancer

Funds: 

The Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences(2019XK320027)

  • 摘要: 前列腺癌是男性生殖系统最常见的恶性肿瘤之一,也是导致男性癌症死亡的第五大原因,早期诊治可改善患者的预后。目前,前列腺癌的诊断主要依赖于直肠指诊或血清前列腺特异性抗原(prostate specific antigen,PSA)检测后,行前列腺穿刺活检确诊。但血清PSA检测特异性较低,不能有效区分惰性前列腺癌与具有临床意义的前列腺癌,导致不必要的活检及过度治疗。因此,迫切需要更具有特异性的肿瘤标志物。前列腺癌细胞可将肿瘤标志物释放至前列腺液中,而后进入尿液,尿液可作为前列腺癌肿瘤标志物的来源。近年来,已开发了多种基于尿液活检的肿瘤标志物,如PSA、PCA3、MALAT1及miRNA等,本文将阐述尿液肿瘤标志物在前列腺癌诊断中的研究进展。
  • [1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71:209-249.
    [2] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet (London, England), 2018, 391:1023-1075.
    [3] Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71:7-33.
    [4] Wong MC, Goggins WB, Wang HH, et al. Global Incidence and Mortality for Prostate Cancer:Analysis of Temporal Patterns and Trends in 36 Countries[J]. Eur Urol, 2016, 70:862-874.
    [5] Draisma G, Etzioni R, Tsodikov A, et al. Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening:Importance of Methods and Context[J].J Natl Cancer Inst, 2009, 101:374-383.
    [6] Salagierski M, Schalken JA. Molecular diagnosis of prostate cancer:PCA3 and TMPRSS2:ERG gene fusion[J]. J Urol, 2012, 187:795-801.
    [7] Fenton JJ, Weyrich MS, Durbin S, et al. Prostate-Specific Antigen-Based Screening for Prostate Cancer:Evidence Report and Systematic Review for the US Preventive Services Task Force[J].JAMA, 2018, 319:1914-1931.
    [8] Eskra JN, Rabizadeh D, Pavlovich CP, et al. Approaches to urinary detection of prostate cancer[J]. Prostate Cancer Prostatic Dis, 2019, 22:362-381.
    [9] Bussemakers MJ, Van Bokhoven A, Verhaegh GW, et al. DD3:a new prostate-specific gene, highly overexpressed in prostate cancer[J]. Cancer Res, 1999, 59:5975-5979.
    [10] Truong M, Yang B, Jarrard DF. Toward the detection of prostate cancer in urine:a critical analysis[J]. J Urol, 2013, 189:422-429.
    [11] Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy[J]. Urology, 2007, 69:532-535.
    [12] Ploussard G, de la Taille A. The role of prostate cancer antigen 3(PCA3) in prostate cancer detection[J]. Expert Rev Anticancer Ther, 2018, 18:1013-1020.
    [13] Lee D, Shim SR, Ahn ST, et al. Diagnostic Performance of the Prostate Cancer Antigen 3 Test in Prostate Cancer:Systematic Review and Meta-analysis[J]. Clin Genitourin Cancer, 2020, 18:402-408.e5.
    [14] Salciccia S, Capriotti AL, Laganà A, et al. Biomarkers in Prostate Cancer Diagnosis:From Current Knowledge to the Role of Metabolomics and Exosomes[J]. International Journal of Molecular Sciences, 2021, 22:4367.
    [15] Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer[J]. Science, 2005, 310:644-648.
    [16] Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer[J]. Clin Cancer Res, 2007, 13:5103-5108.
    [17] Leyten GH, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer[J]. Eur Urol, 2014, 65:534-542.
    [18] Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment[J]. Eur Urol, 2016, 70:45-53.
    [19] Sanda MG, Feng Z, Howard DH, et al. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer[J]. JAMA Oncol, 2017, 3:1085-1093.
    [20] Tosoian JJ, Trock BJ, Morgan TM, et al. Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer:Validation of a Straightforward Clinical Testing Approach[J]. J Urol, 2021, 205:732-739.
    [21] Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer[J]. Oncogene, 2003, 22:8031-8041.
    [22] Luan W, Li L, Shi Y, et al. Long non-coding RNA MALAT1 acts as a competing endogenous RNA to promote malignant melanoma growth and metastasis by sponging miR-22[J]. Oncotarget, 2016, 7:63901-63912.
    [23] Ren S, Peng Z, Mao JH, et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings[J]. Cell Res, 2012, 22:806-821.
    [24] Wang F, Ren S, Chen R, et al. Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer[J]. Oncotarget, 2014, 5:11091-11102.
    [25] Goyal B, Yadav S RM, Awasthee N, et al. Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875:188502.
    [26] Graves HC, Sensabaugh GF, Blake ET. Postcoital detection of a male-specific semen protein. Application to the investigation of rape[J]. N Engl J Med, 1985, 312:338-343.
    [27] Bolduc S, Lacombe L, Naud A, et al. Urinary PSA:a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL[J]. Can Urol Assoc J, 2007, 1:377-381.
    [28] Pannek J, Rittenhouse HG, Evans CL, et al. Molecular forms of prostate-specific antigen and human kallikrein 2(hK2) in urine are not clinically useful for early detection and staging of prostate cancer[J]. Urology, 1997, 50:715-721.
    [29] Occhipinti S, Mengozzi G, Oderda M, et al. Low Levels of Urinary PSA Better Identify Prostate Cancer Patients[J]. Cancers (Basel), 2021, 13:3570.
    [30] Weir EG, Partin AW, Epstein JI. Correlation of serum prostate specific antigen and quantitative immunohistochemistry[J]. J Urol, 2000, 163:1739-1742.
    [31] Augustin H, Hammerer PG, Graefen M, et al. Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy[J]. J Cancer Res Clin Oncol, 2003, 129:662-668.
    [32] Hammarsten P, Josefsson A, Thysell E, et al. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome[J]. Mod Pathol, 2019, 32:1310-1319.
    [33] Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions[J]. J Extracell Vesicles, 2015, 4:27066.
    [34] Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018(MISEV2018):a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines[J]. J Extracell Vesicles, 2018, 7:1535750.
    [35] Zhang Y, Liu Y, Liu H, et al. Exosomes:biogenesis, biologic function and clinical potential[J]. Cell Biosci, 2019, 9:19.
    [36] Boukouris S, Mathivanan S. Exosomes in bodily fluids are a highly stable resource of disease biomarkers[J]. Proteomics Clin Appl, 2015, 9:358-367.
    [37] Donovan M J, Noerholm M, Bentink S, et al. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result[J]. Prostate Cancer Prostatic Dis, 2015, 18:370-375.
    [38] Mckiernan J, Donovan MJ, O'neill V, et al. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy[J]. JAMA Oncol, 2016, 2:882-889.
    [39] Mckiernan J, Donovan M J, Margolis E, et al. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy[J]. Eur Urol, 2018, 74:731-738.
    [40] Mckiernan J, Noerholm M, Tadigotla V, et al. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy[J]. BMC Urol, 2020, 20:138.
    [41] Catalanotto C, Cogoni C, Zardo G. MicroRNA in Control of Gene Expression:An Overview of Nuclear Functions[J]. Int J Mol Sci, 2016, 17:1712.
    [42] Bertoli G, Cava C, Castiglioni I. MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer[J]. Int J Mol Sci, 2016, 17:421.
    [43] Samsonov R, Shtam T, Burdakov V, et al. Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis:Application for prostate cancer diagnostic[J]. Prostate, 2016, 76:68-79.
    [44] Foj L, Ferrer F, Serra M, et al. Exosomal and Non-Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis[J]. Prostate, 2017, 77:573-583.
    [45] Rodríguez M, Bajo-Santos C, Hessvik NP, et al. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes[J]. Mol Cancer, 2017, 16:156.
    [46] Li J, Xu C, Lee H J, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations[J]. Nature, 2020, 580:93-99.
  • 加载中
计量
  • 文章访问数:  21
  • HTML全文浏览量:  0
  • PDF下载量:  6
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-12-05
  • 网络出版日期:  2022-04-07

目录

    /

    返回文章
    返回